Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Alten

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Clinical and Experimental Rheumatology|March 31, 2009
Internet use in rheumatology outpatients in 2006: gender less importantJ G Richter, A Becker, T Koch, et al.
BMC Rheumatology|March 12, 2020
Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world studyA Deodhar, V Strand, P G Conaghan, et al.
Schmerz (Berlin, Germany)|May 22, 2010
[Validation of the German version of the Regional Pain Scale for the diagnosis of fibromyalgia syndrome]W Häuser, S Schild, M Kosseva, et al.
Annals of the Rheumatic Diseases|July 24, 2008
Self-assessments of patients via Tablet PC in routine patient care: comparison with standardised paper questionnairesJ G Richter, A Becker, T Koch, et al.
Schmerz (Berlin, Germany)|July 5, 2012
[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]C Sommer, W Häuser, R Alten, et al.
Deutsche Medizinische Wochenschrift (1946)|October 8, 2009
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]U Müller-Ladner, R Alten, A Heiligenhaus, et al.
Annals of the Rheumatic Diseases|October 31, 2007
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of responseJ Braun, X Baraliakos, J Listing, et al.
Scandinavian Journal of Rheumatology. Supplement|October 12, 2000
Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study GroupL Färber, T Stratz, W Brückle, et al.
Schmerz (Berlin, Germany)|May 12, 2017
[Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles]C Sommer, R Alten, K-J Bär, et al.
The Journal of Rheumatology|February 7, 1998
Importance of psychological well being and disease activity in termination of an initial DMARD therapyJ Listing, R Alten, D Brauer, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Clinical and Experimental Rheumatology|March 31, 2009
Internet use in rheumatology outpatients in 2006: gender less importantJ G Richter, A Becker, T Koch, et al.
BMC Rheumatology|March 12, 2020
Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world studyA Deodhar, V Strand, P G Conaghan, et al.
Schmerz (Berlin, Germany)|May 22, 2010
[Validation of the German version of the Regional Pain Scale for the diagnosis of fibromyalgia syndrome]W Häuser, S Schild, M Kosseva, et al.
Annals of the Rheumatic Diseases|July 24, 2008
Self-assessments of patients via Tablet PC in routine patient care: comparison with standardised paper questionnairesJ G Richter, A Becker, T Koch, et al.
Schmerz (Berlin, Germany)|July 5, 2012
[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]C Sommer, W Häuser, R Alten, et al.
Deutsche Medizinische Wochenschrift (1946)|October 8, 2009
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]U Müller-Ladner, R Alten, A Heiligenhaus, et al.
Annals of the Rheumatic Diseases|October 31, 2007
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of responseJ Braun, X Baraliakos, J Listing, et al.
Scandinavian Journal of Rheumatology. Supplement|October 12, 2000
Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study GroupL Färber, T Stratz, W Brückle, et al.
Schmerz (Berlin, Germany)|May 12, 2017
[Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles]C Sommer, R Alten, K-J Bär, et al.
The Journal of Rheumatology|February 7, 1998
Importance of psychological well being and disease activity in termination of an initial DMARD therapyJ Listing, R Alten, D Brauer, et al.
Pageof 5